While both EGFR and HER2 are excellent targets and a number of targeted therapies have been successfully transformed to the clinic for patients with EGFR- or HER2-mutated NSCLC, there is no Food and Drug Administration (FDA)-approved HER3-targeted therapy for cancer treatment. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.